These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
102 related articles for article (PubMed ID: 1861941)
41. Pharmacokinetics of zidovudine administered intravenously and orally in children with human immunodeficiency virus infection. Balis FM; Pizzo PA; Eddy J; Wilfert C; McKinney R; Scott G; Murphy RF; Jarosinski PF; Falloon J; Poplack DG J Pediatr; 1989 May; 114(5):880-4. PubMed ID: 2715903 [TBL] [Abstract][Full Text] [Related]
42. Zidovudine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Langtry HD; Campoli-Richards DM Drugs; 1989 Apr; 37(4):408-50. PubMed ID: 2661194 [TBL] [Abstract][Full Text] [Related]
43. Combined zidovudine and interferon-alpha 2a therapy in children with acquired immune deficiency syndrome. Giovannini M; Zuccotti GV; Biasucci G; Locatelli V; Riva E J Int Med Res; 1992 Jun; 20(3):295-301. PubMed ID: 1397675 [TBL] [Abstract][Full Text] [Related]
44. Prescription drug use patterns of human immunodeficiency virus-infected patients taking zidovudine. Walter Reed Retrovirus Research Group. Bjornson DC; Meyer DE; Hiner WO; Tramont EC DICP; 1989 Sep; 23(9):698-702. PubMed ID: 2800586 [TBL] [Abstract][Full Text] [Related]
45. The combined toxicity of azidothymidine and antimycobacterial agents. A retrospective study. Kavesh NG; Holzman RS; Seidlin M Am Rev Respir Dis; 1989 May; 139(5):1094-7. PubMed ID: 2712436 [TBL] [Abstract][Full Text] [Related]
46. [Indications and contraindications for zidovudine]. Hirschel B Dtsch Med Wochenschr; 1989 Aug; 114(34):1289-93. PubMed ID: 2670504 [No Abstract] [Full Text] [Related]
47. Treatment of children symptomatic with human immunodeficiency virus infection. Wilfert CM; McKinney R J Infect; 1989 Jan; 18 Suppl 1():81-2. PubMed ID: 2644365 [No Abstract] [Full Text] [Related]
48. Zidovudine-induced neutropenia: are we too cautious? Shaunak S; Bartlett JA Lancet; 1989 Jul; 2(8654):91-2. PubMed ID: 2567882 [TBL] [Abstract][Full Text] [Related]
49. Use of zidovudine for drug misusers infected with human immunodeficiency virus. Cowan FM; Jones G; Bingham J; Flegg PJ; MacCallum LR; Whitelaw J; Hargreave D; Gray JA; Welsby PD; Brettle RP J Infect; 1989 Jan; 18 Suppl 1():59-66. PubMed ID: 2915141 [TBL] [Abstract][Full Text] [Related]
50. Myopathy in human immunodeficiency virus-infected children receiving long-term zidovudine therapy. Walter EB; Drucker RP; McKinney RE; Wilfert CM J Pediatr; 1991 Jul; 119(1 Pt 1):152-5. PubMed ID: 1906098 [No Abstract] [Full Text] [Related]
51. Guidelines for the use of zidovudine for post-exposure prophylaxis after needlestick injuries in health care settings. Sacho H; Schoub BD S Afr Med J; 1990 Jun; 77(12):619-22. PubMed ID: 2288569 [TBL] [Abstract][Full Text] [Related]
52. High-dose IgG for neutropenic patients with acquired immunodeficiency syndrome (AIDS). Salama A; Lohmeyer J; Seeger W; Mueller-Eckhardt C Ann Hematol; 1991 Aug; 63(2):77-8. PubMed ID: 1912034 [TBL] [Abstract][Full Text] [Related]
53. Acquired immunodeficiency syndrome. Cerebrospinal fluid findings in patients before and during long-term oral zidovudine therapy. Tartaglione TA; Collier AC; Coombs RW; Opheim KE; Cummings DK; Mackay SR; Benedetti J; Corey L Arch Neurol; 1991 Jul; 48(7):695-9. PubMed ID: 1859296 [TBL] [Abstract][Full Text] [Related]
54. Bioequivalence assessment of zidovudine (Retrovir) syrup, solution, and capsule formulations in patients infected with human immunodeficiency virus. Drew RH; Weller S; Gallis HA; Walmer KA; Bartlett JA; Blum MR Antimicrob Agents Chemother; 1989 Oct; 33(10):1801-3. PubMed ID: 2589846 [TBL] [Abstract][Full Text] [Related]
55. Nuclear and mitochondrial changes of muscle fibers in AIDS after treatment with high doses of zidovudine. Schröder JM; Bertram M; Schnabel R; Pfaff U Acta Neuropathol; 1992; 85(1):39-47. PubMed ID: 1285495 [TBL] [Abstract][Full Text] [Related]